Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice (2020)
- Authors:
- Autor USP: GIANNELLA, MARIA LUCIA CARDILLO CORREA - FM
- Unidade: FM
- DOI: 10.2147/DMSO.S242282
- Subjects: DIABETES MELLITUS; GLICOSÍDEOS; RATOS; FÍGADO GORDUROSO
- Agências de fomento:
- FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/09463-8, 2017/19449-9]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil (CAPES)CAPES [001]
- Sao Paulo State Foundation for Research (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2016/15603-0]
- Language: Inglês
- Imprenta:
- Source:
- Título: Diabetes metabolic syndrome and obesity-targets and therapy
- ISSN: 1178-7007
- Volume/Número/Paginação/Ano: v. 13, p. 739-751, 2020
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
DAVID-SILVA, Aline et al. Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. Diabetes metabolic syndrome and obesity-targets and therapy, v. 13, p. 739-751, 2020Tradução . . Disponível em: https://doi.org/10.2147/DMSO.S242282. Acesso em: 05 fev. 2026. -
APA
David-Silva, A., Esteves, J. V., Morais, M. R. P. T., Freitas, H. S., Zorn, T. M., Giannella, M. L. C. C., & Machado, U. F. (2020). Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. Diabetes metabolic syndrome and obesity-targets and therapy, 13, 739-751. doi:10.2147/DMSO.S242282 -
NLM
David-Silva A, Esteves JV, Morais MRPT, Freitas HS, Zorn TM, Giannella MLCC, Machado UF. Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice [Internet]. Diabetes metabolic syndrome and obesity-targets and therapy. 2020 ; 13 739-751.[citado 2026 fev. 05 ] Available from: https://doi.org/10.2147/DMSO.S242282 -
Vancouver
David-Silva A, Esteves JV, Morais MRPT, Freitas HS, Zorn TM, Giannella MLCC, Machado UF. Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice [Internet]. Diabetes metabolic syndrome and obesity-targets and therapy. 2020 ; 13 739-751.[citado 2026 fev. 05 ] Available from: https://doi.org/10.2147/DMSO.S242282 - Expression analysis of proto-oncogene ret in patients with primary hyperparathyroidism: comparison between hyperplasia, adenoma and carcinoma
- Continuous glucose monitoring system: dawn period calibration does not change accuracy
- Sex-specific associations of variants in regulatory regions of NADPH oxidase-2 (CYBB) and glutathione peroxidase 4 (GPX4) genes with kidney disease in type 1 diabetes
- Validation of serum MicroRNAs-19a,-24, and-29a as potential markers to differentiate pancreatic cancer-associated diabetes From type 2 diabetes mellitus. [Carta]
- Association between tumor GHSR-IA mRNA expression and in vivo response to GHRP-6 in patients with ACTH-dependent Cushing`s syndrome
- Visceral adiposity syndrome
- Polymorphisms in the gene encoding glucose transporter Glut-1 (SLC2A1) and renal disease in type 1 diabetic patients
- 3111T/clock gene polymorphism is associated with metabolic changes in Brazilian obese children and adolescents
- Celiac crisis in an adult type 1 diabetes mellitus patient: a rare manifestation of celiac disease
- Association between the 308G/A TNF promoter variant insulin resistance and hypertension in obese children
Informações sobre o DOI: 10.2147/DMSO.S242282 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
